Edition:
India

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

3.51USD
16 Feb 2018
Change (% chg)

$-0.01 (-0.28%)
Prev Close
$3.52
Open
$3.50
Day's High
$3.67
Day's Low
$3.49
Volume
84,193
Avg. Vol
32,635
52-wk High
$5.11
52-wk Low
$2.70

Chart for

About

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $238.49
Shares Outstanding(Mil.): 50.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.64
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial

* MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL

12 Dec 2017

BRIEF-Fortress Biotech forms subsidiary Tamid Bio to develop novel aav gene therapies in Orphan Diseases

* FORTRESS BIOTECH FORMS SUBSIDIARY TAMID BIO TO DEVELOP NOVEL AAV GENE THERAPIES IN ORPHAN DISEASES WITH UNMET MEDICAL NEEDS Source text for Eikon: Further company coverage:

05 Dec 2017

BRIEF-Mustang Bio names new vice president of finance and corporate controller

* Mustang Bio announces appointment of Brian Achenbach as vice president of finance and corporate controller Source text for Eikon: Further company coverage:

14 Nov 2017

BRIEF-Fortress Biotech posts Q3 loss per share $0.67

* Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights

10 Nov 2017

BRIEF-Fortress Biotech announces pricing of series a preferred stock offering

* Fortress Biotech Inc announces pricing of series a preferred stock offering

07 Nov 2017

BRIEF-Fortress Biotech proposes public offering of Series A preferred stock

* Fortress Biotech announces proposed public offering of Series A preferred stock Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Mustang Bio enters lease agreement for production of Car T therapies

* Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​

30 Oct 2017

Earnings vs. Estimates